Medical Condition News

RSS

Special issue of Progress in Cardiovascular Diseases

High altitude medicine is a "natural research laboratory" for the study of cardiovascular physiology and pathophysiology. As such, it can shed light on conditions and diseases that mimic the low oxygen content of the atmosphere at the top of mountains.

5 May 2010

HbA1c can be deceptive in African American children with diabetes: Study

Researchers at LSU Health Sciences Center New Orleans and Children's Hospital of New Orleans have found that there is a major difference in the hemoglobin A1c response to blood glucose between African-American and Caucasian children with diabetes. HbA1c is the main test used to monitor diabetes and guide treatment decisions.

5 May 2010

Palatin Technologies granted patent relating to small molecule compounds that bind to melanocortin receptors

Palatin Technologies, Inc. announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,709,484, titled "Substituted Melanocortin Receptor-Specific Piperazine Compounds," today. The claims in the issued patent relate to small molecule compounds which bind to melanocortin receptors.

5 May 2010

Three Hamilton scientists receive cancer research grants from Canadian Cancer Society

Three Hamilton scientists are receiving new funding from the Canadian Cancer Society for their work in innovative cancer research.

5 May 2010

FDA's call for further review of pirfenidone disappointing for Pulmonary Fibrosis patients, says CPF

The Coalition for Pulmonary Fibrosis (CPF), representing tens of thousands of patients, is responding to the news that the FDA chose to ask for further study of Pirfenidone, which will delay potential approval of the first drug in the treatment of Pulmonary Fibrosis (PF), a lethal lung disease that is irreversible, progressive and deadly in an average of three years. On March 9, 2010, an FDA Advisory Committee recommended approval of the drug by the FDA.

5 May 2010

Protein PEA-15 stops T-cell proliferation

New research has identified that a key protein called PEA-15 stops T-cell proliferation by blocking the cell's ability to reproduce. The control of T-cell proliferation is essential in preventing certain blood cancers and autoimmune diseases, as well as the orchestration of the immune response to infection. Findings of the study are reported in a recent online issue of The FASEB Journal, a publication of The Federation of American Societies for Experimental Biology.

5 May 2010

New treatments for intestinal failure, other intestinal absorption disorders

New treatments for intestinal failure and other intestinal absorption disorders are a step closer to the patients who need them after a discovery in Kelly Tappenden's University of Illinois laboratory.

5 May 2010

Researchers analyze role of gender in treatment and outcome of patients with MMD

Moyamoya disease is an uncommon, progressive cerebrovascular disease in which the main arteries feeding the brain (the intracranial internal carotid arteries/ICA and Circle of Willis) are narrowed or occluded on both sides, reducing blood flow to the brain. This causes transient episodes of reversible stroke with loss of neurologic function in the form of weakness of a limb, sensory disturbances, epileptic seizures or headaches.

5 May 2010

Americans and their babies are gaining more body fat: Study

A new study has found for the first time that as Americans are gaining more body fat, so are their babies. The research, which reviewed data from more than 74,000 births, found that a key measure of body fat composition in newborns increased significantly over a 15-year period, mirroring similar increases among pregnant mothers. The findings were presented Sunday by researchers from Children's Mercy Hospitals and Clinics at the Pediatric Academic Societies annual meeting.

5 May 2010

New pathology test may help doctors distinguish between two overlapping esophageal disorders: Study

A pathology test may help doctors distinguish between two separate but overlapping esophageal disorders that require different courses of treatment, according to a study by researchers at the University of North Carolina at Chapel Hill.

5 May 2010

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announced at BIO2010 in Chicago that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, has been approved in the UK by the Gene Therapy Advisory Committee and by the Medicines and Healthcare products Regulatory Agency Medicines Division.

5 May 2010

Study investigates pilot VBBD program to improve adherence to diabetes medications

A recent study led by MedImpact Healthcare Systems, Inc. investigated a pilot Value-Based Benefit Design program to improve adherence to diabetes medications. The study found that a VBBD program that reduced copayments for diabetes medications by 36 percent reduced the number of non-adherent patients by 30 percent.

5 May 2010

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug.

5 May 2010

Ventral striatum plays important role in circuitry of reward-oriented behavior: Researchers

An estimated 26.2 percent of Americans ages 18 and older - about one in four adults - suffer from a diagnosable mental disorder every year, which equates to approximately 57.7 million adults. Severe psychiatric illness affects a much smaller number of people - about 6 percent, or 1 in 17. Worldwide, an estimated 340 million people suffer from an episode of major depression every year.

5 May 2010

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.

5 May 2010

TCT for Surgeons to showcase hybrid surgical, interventional techniques during TCT 2010

TCT for Surgeons will showcase the expansion of hybrid surgical and interventional techniques in the field that are improving outcomes for patients undergoing cardiac surgery. Now in its 4th year, the course will run during Transcatheter Cardiovascular Therapeutics 2010 (September 21-25), the annual scientific symposium of the Cardiovascular Research Foundation.

5 May 2010

Azithromycin does not improve lung function in children with cystic fibrosis

Children and adolescents with cystic fibrosis who received the antibiotic azithromycin did not experience improved lung function, compared to patients who received placebo, according to a study in the May 5 issue of JAMA.

5 May 2010

UVA exposure at early age does not cause melanoma

Early life exposure to ultraviolet A light does not cause melanoma in a fish model that previously made that connection, scientists from The University of Texas MD Anderson Cancer Center reported today in the online Early Edition of the Proceedings of the National Academy of Sciences.

5 May 2010

ZEGERID OTC capsules offer more rapid acid reduction than Prevacid- 24HR delayed-release capsules

Merck Consumer Care today announced results of a head-to-head clinical study showing that ZEGERID OTC- offers greater and faster acid control than Prevacid- 24HR. While acid control is an industry standard measure for acid-reducing drugs, greater and faster acid control does not imply greater and faster heartburn symptom relief.

5 May 2010

Physically active lifestyle during adolescence can reduce effect of mutation in FTO gene: Study

The FTO gene is obesity's main ally. Several studies are now attempting to reveal the factors that play a key role in fighting against it. A new study led by Spanish researchers shows that a physically active lifestyle during adolescence can reduce the effect of a mutation in this gene which predisposes someone to becoming overweight or obese.

5 May 2010

Medical Condition News

Special issue of Progress in Cardiovascular Diseases

HbA1c can be deceptive in African American children with diabetes: Study

Palatin Technologies granted patent relating to small molecule compounds that bind to melanocortin receptors

Three Hamilton scientists receive cancer research grants from Canadian Cancer Society

FDA's call for further review of pirfenidone disappointing for Pulmonary Fibrosis patients, says CPF

Protein PEA-15 stops T-cell proliferation

New treatments for intestinal failure, other intestinal absorption disorders

Researchers analyze role of gender in treatment and outcome of patients with MMD

Americans and their babies are gaining more body fat: Study

New pathology test may help doctors distinguish between two overlapping esophageal disorders: Study

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Study investigates pilot VBBD program to improve adherence to diabetes medications

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

Ventral striatum plays important role in circuitry of reward-oriented behavior: Researchers

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

TCT for Surgeons to showcase hybrid surgical, interventional techniques during TCT 2010

Azithromycin does not improve lung function in children with cystic fibrosis

UVA exposure at early age does not cause melanoma

ZEGERID OTC capsules offer more rapid acid reduction than Prevacid- 24HR delayed-release capsules

Physically active lifestyle during adolescence can reduce effect of mutation in FTO gene: Study

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News